Form 4: Ultragenyx CEO Emil Kakkis Reports Stock Transactions

Ultragenyx Pharmaceutical Inc. CEO Emil Kakkis reports acquisition and disposal of company stock and derivative securities.

Summary

• On March 1, 2025, Emil Kakkis acquired 43,268 shares of common stock through Restricted Stock Units (RSUs) and 107,292 shares through the conversion of performance stock units.
• Also on March 1, 2025, Kakkis was granted options to purchase 78,448 shares of common stock at an exercise price of $42.92, vesting over four years.
• On March 3, 2025, Kakkis sold 73,434 shares of common stock at an average price of $42.1 to cover tax withholdings related to the vesting of RSUs.
• On February 28, 2025, Kakkis sold 25,000 shares of common stock at an average price of $42.48.
• Following these transactions, Kakkis directly owns 641,731 shares and indirectly owns 2,158,985 shares through a living trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. The sale of shares to cover taxes is a common practice.

Positives

• The acquisition of shares through RSUs and performance stock units conversion indicates confidence in the company's future performance.
• The granting of stock options aligns management's interests with those of shareholders.

Negatives

• The sale of shares to cover tax obligations, while common, could be perceived negatively by some investors.

Risks

• Future stock sales by Kakkis could put downward pressure on the stock price.

Future Outlook

The RSUs vest in equal installments over four years from the grant date, and the stock options vest similarly, indicating a long-term commitment from the CEO.

Industry Context

Insider transactions are common in the pharmaceutical industry, especially following the vesting of equity awards. Investors often monitor these transactions for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices in the pharmaceutical industry to incentivize executives.
• Vesting schedules of four years are typical for such awards.
• Monitoring insider transactions is a common practice among investors in companies like Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into management's perspective on the company's value.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates